Loading company
$3.14-0.6%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 27, 2026
Past performance
- 1W
- -6.8%
- 1M
- -1.7%
- 3M
- -42.1%
- 6M
- -53.7%
- 1Y
- -55.7%
- 5Y
- -33.9%
$3.14-0.6%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 27, 2026
Just reported
From Wave Life Sciences, Inc.'s results release of October 27, 2026; its quarterly report has since been filed.
Actual
$13.2M
+73% y/y
Guided
—
No guide given
Actual
-$0.30
Guided
—
No guide given
Actual
-$66M
Guided
—
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $13.2M | $7.6M | +72.95% |
| Profit | -$61.9M | -$53.9M | -14.97% |
| Profit per share | -$0.30 | -$0.32 | +6.25% |
| Free Cash Flow | -$60.2M | -$44.9M | -33.94% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Wave Life Sciences, Inc. has no earnings call transcript available.
“We continue to make notable progress advancing our lead clinical programs. Following positive FDA feedback, planning is underway for our potentially registrational trial of WVE-006 for AATD, which we believe offers an efficient path to potential full and accelerated approval, without the need for a separate confirmatory trial. Our growing body of clinical data support WVE-006’s potential to offer a new standard of care for individuals living with AATD,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM ® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s lead pipeline programs include obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 I148M liver disease (WVE-008), as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Wave Life Sciences, Inc.’s Item 2.02 8-K filed October 27, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.